Creative Medical Technology Holdings（CELZ）株式概要クリエイティブ・メディカル・テクノロジー・ホールディングス社は、商業段階のバイオテクノロジー企業であり、米国において免疫療法、内分泌学、泌尿器学、神経学、整形外科学の分野における新規生物学的治療薬に注力している。 詳細CELZ ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長3/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間55.26%増加すると予測されています リスク分析収益が 100 万ドル未満 ( $6K )過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( $8M )すべてのリスクチェックを見るCELZ Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$2.2415.9k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-36m19m2016201920222025202620282031Revenue US$58.4kEarnings US$10.0kAdvancedSet Fair ValueView all narrativesGANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.3% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2325429d agoCreative Medical Technology Holdings, Inc. 競合他社SoligenixSymbol: NasdaqCM:SNGXMarket cap: US$3.6mVivoSim LabsSymbol: NasdaqCM:VIVSMarket cap: US$4.1mBioCardiaSymbol: NasdaqCM:BCDAMarket cap: US$12.5mAptorum GroupSymbol: NasdaqCM:APMMarket cap: US$7.1m価格と性能株価の高値、安値、推移の概要Creative Medical Technology Holdings過去の株価現在の株価US$2.2452週高値US$6.2552週安値US$1.50ベータ1.991ヶ月の変化12.56%3ヶ月変化10.89%1年変化12.00%3年間の変化-65.00%5年間の変化-98.74%IPOからの変化-99.90%最新ニュースCreative Medical Technology Holdings, Inc. Reports Breakthrough Response Rate in Ultrasome Knee Osteoarthritis Program and Expands CELZ-201 Platform Into Scalable Cell-Free Regenerative TherapiesApr 30Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 23New major risk - Share price stability Jan 14Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back PainJan 13Forecast to breakeven in 2028 Dec 31Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection PointDec 18最新情報をもっと見るRecent updatesCreative Medical Technology Holdings, Inc. Reports Breakthrough Response Rate in Ultrasome Knee Osteoarthritis Program and Expands CELZ-201 Platform Into Scalable Cell-Free Regenerative TherapiesApr 30Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 23New major risk - Share price stability Jan 14Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back PainJan 13Forecast to breakeven in 2028 Dec 31Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection PointDec 18Creative Medical Technology Holdings Announces World Health Organization Approval of "Olastrocel" as Inn for Lead Allogeneic Cell Therapy Celz-201Dec 02No longer forecast to breakeven Nov 09Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 18, 2025Oct 31Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back PainAug 14Second quarter 2025 earnings released: US$0.48 loss per share (vs US$1.11 loss in 2Q 2024) Aug 11 Aug 10New major risk - Market cap size Jun 01Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating May 12 May 11New major risk - Shareholder dilution Apr 25Creative Medical Technology Holdings Provides Nasdaq Compliance UpdateApr 12Forecast breakeven date pushed back to 2027 Mar 16New major risk - Share price stability Mar 06Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™Feb 14Creative Medical Technology Reports Positive One-Year Results for Allostem™? Type 2 Diabetes ProgramFeb 11Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back PainJan 30Insufficient new directors Jan 02Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain TreatmentNov 14New minor risk - Shareholder dilution Nov 06Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.Oct 24New minor risk - Share price stability Sep 10Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human InsulinJun 24Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024May 21Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 24New minor risk - Share price stability Mar 08Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded AccessMar 07Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStemDec 20New major risk - Financial position Nov 17Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023Nov 04Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back PainOct 11Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back PainSep 20Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing RequirementsJun 30Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.Jun 13Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy PlatformJun 01Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform DevelopmentMay 23Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell LineMay 19Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot StudyFeb 15Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 DiabetesFeb 09High number of new and inexperienced directors Nov 16Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 DiabetesNov 04Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022Oct 27Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell LineOct 21Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot StudyJul 29Creative Medical Technology Holdings Receives Non-Compliance Notice from NasdaqJul 16Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in fundingMay 06High number of new and inexperienced directors Apr 27Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® ProductApr 21Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 01Creative Medical Technology Appoints Sahil Nock as Chief Commercial OfficerMar 04High number of new and inexperienced directors Jan 02Creative Medical Technology Holdings Deleted from Other OTCDec 05Less than half of directors are independent Dec 04Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in fundingAug 13Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in fundingAug 10Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 DiabetesJun 10Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's DiseaseMay 25FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke TreatmentMay 15Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat StrokeMar 17Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell TherapyMar 05Creative Medical Technology Holdings Provides Update on ImmCelz® FDA ApplicationMar 04Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz®Feb 18Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure TreatmentFeb 11Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory BoardFeb 09Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic ActivityFeb 02Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory BoardJan 22+ 1 more updateCreative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative ImmunotherapyJan 13Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative ImmunotherapyJan 01Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of StrokeDec 18Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular ImmunotherapyDec 13Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis ModelSep 30株主還元CELZUS BiotechsUS 市場7D-2.6%-2.5%0.8%1Y12.0%26.8%27.7%株主還元を見る業界別リターン: CELZ過去 1 年間で26.8 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: CELZは、過去 1 年間で27.7 % のリターンを上げたUS市場を下回りました。価格変動Is CELZ's price volatile compared to industry and market?CELZ volatilityCELZ Average Weekly Movement7.8%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.3%安定した株価: CELZ 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: CELZの 週次ボラティリティ は、過去 1 年間で14%から8%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a4Tim Warbingtonwww.creativemedicaltechnology.comクリエイティブ・メディカル・テクノロジー・ホールディングス社は、商業段階のバイオテクノロジー企業であり、米国では免疫療法、内分泌学、泌尿器学、神経学、整形外科学の分野における新規生物学的治療薬に注力している。同社は、勃起不全を治療するCaverStemと、性器の感度低下と乾燥の治療薬FemCelzを提供している。同系ヒト周産期組織由来細胞プログラムであるAlloStem（CELZ-201-DDT）、個別化スーパーチャージ免疫療法プラットフォームであるImmCelz（CELZ-100）、1型糖尿病治療薬としてフェーズ2のCELZ-201 CREATE-1、慢性腰痛治療薬としてフェーズ2のAlloStemSpine（CELZ 201 ADAPT）を開発している；早発卵巣不全による不妊症を治療するプラットフォーム「Alova」、変性椎間板症を治療する再生幹細胞治療法「StemSpine」、早発卵巣不全の幹細胞治療法「OvaStem」、勃起不全治療薬「CaverStem」、女性の性機能治療薬「FemCelz」などがある。さらに、移植臓器の拒絶反応の予防、腎不全、肝不全、心臓発作、パーキンソン病など、さまざまな適応症の製品やサービスを開発している。クリエイティブ・メディカル・テクノロジー・ホールディングスはアリゾナ州フェニックスに本社を置いている。もっと見るCreative Medical Technology Holdings, Inc. 基礎のまとめCreative Medical Technology Holdings の収益と売上を時価総額と比較するとどうか。CELZ 基礎統計学時価総額US$8.32m収益（TTM）-US$6.00m売上高(TTM)US$6.00k1,380xP/Sレシオ-1.4xPER（株価収益率CELZ は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CELZ 損益計算書（TTM）収益US$6.00k売上原価US$2.19k売上総利益US$3.81kその他の費用US$6.00m収益-US$6.00m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-1.62グロス・マージン63.43%純利益率-99,916.80%有利子負債／自己資本比率0.2%CELZ の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 06:12終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Creative Medical Technology Holdings, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jonathan AschoffRoth Capital Partners
GANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.3% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2325429d ago
Creative Medical Technology Holdings, Inc. Reports Breakthrough Response Rate in Ultrasome Knee Osteoarthritis Program and Expands CELZ-201 Platform Into Scalable Cell-Free Regenerative TherapiesApr 30
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back PainJan 13
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection PointDec 18
Creative Medical Technology Holdings, Inc. Reports Breakthrough Response Rate in Ultrasome Knee Osteoarthritis Program and Expands CELZ-201 Platform Into Scalable Cell-Free Regenerative TherapiesApr 30
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back PainJan 13
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection PointDec 18
Creative Medical Technology Holdings Announces World Health Organization Approval of "Olastrocel" as Inn for Lead Allogeneic Cell Therapy Celz-201Dec 02
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back PainAug 14
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™Feb 14
Creative Medical Technology Reports Positive One-Year Results for Allostem™? Type 2 Diabetes ProgramFeb 11
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back PainJan 30
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain TreatmentNov 14
Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.Oct 24
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human InsulinJun 24
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded AccessMar 07
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStemDec 20
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back PainOct 11
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back PainSep 20
Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.Jun 13
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy PlatformJun 01
Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform DevelopmentMay 23
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell LineMay 19
Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot StudyFeb 15
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 DiabetesFeb 09
Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 DiabetesNov 04
Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in fundingMay 06
Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® ProductApr 21
Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in fundingAug 13
Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in fundingAug 10
Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 DiabetesJun 10
Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's DiseaseMay 25
FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke TreatmentMay 15
Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat StrokeMar 17
Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell TherapyMar 05
Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz®Feb 18
Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure TreatmentFeb 11
Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory BoardFeb 09
Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic ActivityFeb 02
Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory BoardJan 22+ 1 more update
Creative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative ImmunotherapyJan 13
Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative ImmunotherapyJan 01
Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of StrokeDec 18
Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular ImmunotherapyDec 13
Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis ModelSep 30
